Your session is about to expire
← Back to Search
ALXN1720 for Myasthenia Gravis
Study Summary
This trial will test a new drug, ALXN1720, for the treatment of generalized myasthenia gravis (gMG) in adults. gMG is a disease where the body's immune system attacks healthy cells, causing muscle weakness. The new drug is designed to stop the immune system from attacking healthy cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a positive blood test for autoantibodies against AChR.You have had an infection with Neisseria meningitidis in the past.You have a positive blood test for certain antibodies related to muscle function.I had surgery on my thymus gland within the last year.I have an untreated cancer of the thymus.I have been diagnosed with MG and experience widespread muscle weakness.
- Group 1: ALXN1720
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many patients are you enrolling in this research project?
"That is accurate. The clinicaltrials.gov website has information revealing that this trial is open for recruitment. The trial was first posted on December 16th, 2022 and was last updated on October 17th, 2022. The study needs 254 individuals from 1 location."
Are there still positions available for trial participants?
"That is correct, the information on clinicaltrials.gov verifies that this trial is still looking for patients. The trial was posted on December 16th, 2022 and was last updated more recently on October 17th, 2022. So far, 254 people have signed up across 1 location."
Has ALXN1720 received regulatory approval from the US Food and Drug Administration?
"There is some evidence for efficacy and safety, as this is a Phase 3 trial, so we give it a 3."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger